Grant List
Represents Grant table in the DB
GET /v1/grants?sort=program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=program_officials", "prev": null }, "data": [ { "type": "Grant", "id": "10651", "attributes": { "award_id": "75N95022P00438-0-0-1", "title": "N3C OPEN DATA PORTAL AND COMMUNITY ENGAGEMENT SUPPORT SERVICES FOR NCATS (COVID-19 ACTION)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)", "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-02", "end_date": "2023-09-01", "award_amount": 3295541, "principal_investigator": { "id": 24128, "first_name": "SUHAS", "last_name": "SHARMA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [ "Area", "Award", "Businesses", "COVID-19", "COVID-19 patient", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Complex Analysis", "Contracts", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Development", "Electronic Health Record", "Ensure", "Environment", "Genomics", "Health", "Image", "Informatics", "Information Technology", "Ingestion", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Pathology", "Privacy", "Productivity", "Pythons", "Radiology Specialty", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Security", "Services", "Statistical Data Interpretation", "Translational Research", "United States", "United States National Institutes of Health", "Viral", "Visualization", "Work", "analytical tool", "cloud based", "cohort", "community engagement", "coronavirus disease", "data enclave", "data harmonization", "data portal", "genetic variant", "meetings", "multimodal data", "open data", "open source", "open source tool", "programs", "protective factors", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "10475", "attributes": { "award_id": "272201700036I-0-759302200001-1", "title": "Task A68: Screening Vaccine (and Other Biologics) Platform Technologies using Coronavirus Mouse Immunogenicity as a Model System", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-05-23", "end_date": "2023-12-22", "award_amount": 563541, "principal_investigator": { "id": 22321, "first_name": "RALPH", "last_name": "BARIC", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This contract provides for the development and standardization of small animal models of infectious diseases, and may include efficacy testing of candidate products, including GLP studies to support licensure.", "keywords": [ "Animal Model", "Biological Models", "Biological Products", "COVID-19 vaccine", "Contracts", "Coronavirus", "Development", "Evaluation", "Licensure", "Mus", "Standardization", "Technology", "efficacy testing", "immunogenicity", "infectious disease model", "vaccine evaluation" ], "approved": true } }, { "type": "Grant", "id": "10571", "attributes": { "award_id": "1U01IP001182-01", "title": "RFA-IP-22-004, Multidisciplinary Approach to Understanding Vaccine Efficacy and Transmission of Viral Respiratory Tract Infections in the Real World", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2027-09-29", "award_amount": 2483947, "principal_investigator": { "id": 26592, "first_name": "Stacey", "last_name": "House", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 827, "ror": "", "name": "WASHINGTON UNIVERSITY", "address": "", "city": "", "state": "MO", "zip": "", "country": "United States", "approved": true }, "abstract": "– COMPONENT A Influenza and SARS-CoV-2 are major causes of morbidity and mortality and constitute the leading causes of vaccine preventable deaths in the United States. A better understanding of vaccine effectiveness for these viral pathogens is critical to drive public health decisions and interventions. We propose utilizing a multidisciplinary approach to conduct a test-negative study to determine influenza and SARS-CoV-2 vaccine effectiveness in ambulatory patients with respiratory tract infections. The team of investigators includes experts in emergency medicine, infectious disease, pediatrics, epidemiology, information technology, molecular microbiology, virology, and genetics. This team has extensive experience in automated electronic medical record alerts, high-volume subject recruitment of ambulatory patients with respiratory tract infections, rapid escalation/de-escalation of recruitment efforts to match viral circulation patterns, respiratory and blood sample processing and shipment, quality data collection and verification, and viral genomic sequencing necessary to ensure the success of this project. The proposed study will encompass the following specific aims: 1)Utilize innovative automated alerting strategies to identify and recruit a diverse population of ambulatory patients with acute respiratory illnesses; 2) Estimate influenza and SARS-CoV-2 vaccine effectiveness using a test- negative study design in the general population as well as different demographic subgroups.; 3) Explore factors that influence influenza and SARS-CoV-2 vaccine effectiveness such as co-morbidities, vaccination type and schedule, and social determinants of health; 4) Determine effect of viral vaccination status on health outcomes in ambulatory patients with influenza and SARS-CoV-2 infection; 5) Contribute biospecimens and viral genomic sequencing data to a national repository of subjects with PCR-confirmed influenza or SARS-CoV-2 infection. To accomplish these goals, we will enroll at least 1000 ambulatory patients/year with acute respiratory tract infections in the proposed study. The subject population will be identified from the emergency departments of 3 large hospitals in the St. Louis area and their associated outpatient clinics. The available patient population at these enrolling sites is diverse with respect to race, ethnicity, age, socioeconomic status, and medical care access which will enhance the generalizability of the study outcomes to the US population.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5448", "attributes": { "award_id": "0621292", "title": "Conference on Recent Advances in Nonlinear Partial Differential Equations", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "APPLIED MATHEMATICS" ], "program_reference_codes": [], "program_officials": [], "start_date": "2006-05-01", "end_date": "2007-04-30", "award_amount": 25000, "principal_investigator": { "id": 19005, "first_name": "Stephanos", "last_name": "Venakides", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "This award will fund travel and local expenses of 20 young mathematicians to attend and make poster presentations at the workshop on \"Recent Advances in Nonlinear Partial Differential Equations,\" to be held in Toledo, Spain, June 7-10, 2006.\n\nThe workshop will focus on the modern theory of partial differential equations and its applications. Topics to be discussed by the 19 invited speakers include conservation laws, transonic flows, hydrodynamics and vortical structures, turbulence, dispersive waves, combustion, materials science, dynamics of the brain. The workshop will highlight the role of mathematics in these application areas. By bringing leading experts together with a large number of scientists working in these fields, many of them at the early stages of their careers, the workshop will serve as a forum for the dissemination of new scientific ideas and discoveries and will enhance scientific communcation. The poster presentations will give the junior participants an opportunity to exchange ideas with experienced researchers and thus stimulate the best talents in the field.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10403", "attributes": { "award_id": "2149551", "title": "Deep learning-based serological test for point-of-care analysis of COVID-19 immunity with a paper-based multiplexed sensor", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Engineering (ENG)", "CCSS-Comms Circuits & Sens Sys" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-15", "end_date": "2025-08-31", "award_amount": 393222, "principal_investigator": { "id": 4172, "first_name": "Aydogan", "last_name": "Ozcan", "orcid": null, "emails": "[email protected]", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 151, "ror": "", "name": "University of California-Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 151, "ror": "", "name": "University of California-Los Angeles", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Deep learning-based serological test for point-of-care analysis of COVID-19 immunity with a paper-based multiplexed sensor\n\nAbstract: \n\nCOVID-19, caused by the virus SARS-CoV-2, was declared a pandemic by the World Health Organization (WHO) on March 12, 2020. Diagnostic testing has been a critical focus of the response, with an urgent need to rapidly develop, scale, and distribute new tests. Despite all the successful testing methods developed for the direct detection of SARS-CoV-2 genetic material, there is still an urgent need to create new serological assays that can detect virus-specific antibodies as they can ascertain complementary information to direct detection methods by indicating previous exposure and potential immunity, especially important due to various emerging variants. In addition, as vaccines against new variants roll out, these serological tests can be used to evaluate the efficacy of vaccination campaigns, including the ability to elicit SARS-CoV-2 and variant antigen-specific antibodies across vaccinated and unvaccinated populations. In contrast to the current direct detection methods, serology tests that detect antibodies can be low-cost and conducive to a point-of-care (POC) setting, enabling broad screening efforts like widespread immunity testing to indicate individuals in need of vaccine boosters, qualify individuals for travel, return to work, and/or identify convalescent plasma donors. To serve this urgent need, this project will create a smartphone-based, cost-effective platform that can sense and measure the many different antibodies specific to SARS-CoV-2 a person may develop, in a testing format that is easy to use and can be completed within 15 min using an inexpensive paper-based test. \n\nThe team of researchers will develop a multiplexed POC immunoassay and serodiagnostic algorithm that will infer the vaccination/immunity status from up to 10 unique immunoreactions to distinguish an array of SARS-CoV-2 antibodies. For this, the research team will create a multiplexed vertical flow assay (xVFA) to simultaneously detect IgA, IgM, and IgG antibodies to the S protein (as well as variants of the S protein, such as delta, lambda, and other emerging variants), with separate immunoreaction sites dedicated to S-1, S-2, and the receptor-binding domain (RBD) of the S-protein in the SARS-CoV-2 virus and its most recent variants. Using existing and de-identified human serum samples, with the xVFA platform, the research team will screen COVID-19-positive samples, including those resulting from common variants (confirmed through reverse transcriptase-Polymerase Chain Reaction and sequencing) along with vaccinated samples and pre-pandemic un-vaccinated negative control samples. A neural network will then be trained using quantitative information from the multiplexed immunoreactions and the ground-truth clinical state over a set of remnant human serum samples. This training phase will (1) create a serodiagnostic algorithm to identify a positive immune response to SARS-CoV-2 infection (including common variants) or vaccination status using the multiplexed antibody measurements, and (2) identify the key subset of antibody-antigen interactions that most accurately represent and quantify an immune response to SARS-CoV-2 infection or protection via vaccination. A blinded testing phase will benchmark the performance enhancement of the multiplexed and data-driven approach to rigorously validate the trained inference network's generalization. By validating a new multiplexed vertical flow assay and serodiagnosis algorithm for COVID-19 immune protection, the research team aims to determine the significant improvements in sensitivity and specificity gained through the multiple measurements and computational analysis, which come with little added cost or operational steps, or required sample volume. This project will also establish a complementary educational outreach program that will involve (1) public interviews and popular science articles in news media and the internet; (2) undergraduate research opportunities involving underrepresented students; and (3) graduate student training through the organization of workshops, seminars and conferences.\n\nThis award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5286", "attributes": { "award_id": "0810026", "title": "SBIR Phase I: Highly Efficient CdTe Thin Film Solar Cells with Ordered Structure", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Technology, Innovation and Partnerships (TIP)", "SBIR Phase I" ], "program_reference_codes": [], "program_officials": [], "start_date": "2008-07-01", "end_date": "2008-12-31", "award_amount": 99998, "principal_investigator": { "id": 18613, "first_name": "Lisen", "last_name": "Cheng", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 1389, "ror": "", "name": "NanoGreen Solutions Corporation", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1389, "ror": "", "name": "NanoGreen Solutions Corporation", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "This Small Business Innovation Research (SBIR) Phase I project addresses an innovative device fabrication process and bulk hetero-junction structure to fabricate CdTe solar cells with unprecedented performance. Today's crystalline silicon based solar cell technologies are not cost effective as a viable alternative to existing energy sources. CdTe based solar cells have shown very promising as a low cost alternative to current crystalline silicon solar cells. However, the energy conversion efficiency of commercial CdTe solar cells is only ~ 10%. With this innovative approach it is intended to improve energy conversion efficiency up to the limit efficiency of ~29% for CdTe based solar cells, representing a real breakthrough in thin film solar cells and leading to tremendously wide applications.\n\nWorld solar photovoltaic (PV) market installations reached a record high of 1,744 megawatts (MW) in 2006, representing growth of 19% over the previous year. World solar cell production reached a consolidated figure of 2,204 MW in 2006, up from 1,656 MW a year earlier. Global industry revenues were $10.6bn in 2006. According to a new report from Solarbuzz, LLC, annual worldwide industry revenues will reach between $18.6bn and $31.5bn by 2011. Currently, the solar cell market is dominated by crystalline silicon solar cells with a market share of ~93%. If successful the proposed approach can improve the energy efficiency of CdTe based solar cells to the next level, which enables them to compete with (even outperform) current crystalline silicon solar cells. With improved efficiency and low cost, CdTe solar cells will get a significant share of the solar market. There is an extensive range of applications where solar cells are already viewed as the best option for electricity supply such as ocean navigation aids, telecommunication systems, remote monitoring and control, rural electrification, space power and domestic power supply. The proposed green technology harvests solar energy, reducing the emission of CO2 and global warming. This program also provides a route to enhance scientific and technological understanding of crystal growth process at the nano-scale.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10419", "attributes": { "award_id": "1P01AI165066-01", "title": "Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-22", "end_date": "2025-08-31", "award_amount": 1244471, "principal_investigator": { "id": 11662, "first_name": "Daniel", "last_name": "Kulp", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1141, "ror": "", "name": "WISTAR INSTITUTE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1141, "ror": "", "name": "WISTAR INSTITUTE", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "The first project of our pan-CoV proposal is titled ‘Development of broad nanovaccines targeting diverse coronavirus receptor-binding sites’. Our team’s expertise will culminate in structurally guided coronavirus nanoparticle vaccines to broaden CoV vaccine protection. This proposal utilizes our novel platform to develop potent, RBS-focused nanoparticle vaccines to induce broad protection across CoV lineages, escape mutations and potential pandemic CoVs that are of concern. The project aims are: (1) Create a library of mutants that escape coronavirus immunity (2) Develop RBS-focused nanoparticle vaccines to induce broadly neutralizing antibodies to conserved sites using nucleic acid delivery and (3) Develop vaccine regimens to induce broad immunity and protection across diverse CoVs.", "keywords": [ "2019-nCoV", "Address", "Adjuvant", "Antibodies", "Antibody Repertoire", "Antibody Response", "Antigens", "Automobile Driving", "B-Lymphocytes", "Binding", "Binding Sites", "CD8-Positive T-Lymphocytes", "COVID-19 therapeutics", "COVID-19 vaccination", "COVID-19 vaccine", "Coronavirus", "Coronavirus Infections", "Cryoelectron Microscopy", "DNA", "DNA Vaccines", "Development", "Devices", "Disease Outbreaks", "Dose", "Electroporation", "Epitopes", "Escape Mutant", "FDA Emergency Use Authorization", "Frequencies", "Generations", "Genetic", "Genetic Recombination", "Human", "Immune Sera", "Immune response", "Immunity", "Immunization", "Immunization Programs", "Investigation", "Libraries", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Molecular", "Mutagenesis", "Mutate", "Mutation", "Nucleic Acids", "Phenotype", "Preclinical Testing", "Publishing", "Regimen", "Research Project Grants", "SARS coronavirus", "SARS-CoV-2 spike protein", "Site", "Technology", "Transgenic Animals", "Vaccine Clinical Trial", "Vaccines", "Variant", "Virus", "Widespread Disease", "animal data", "base", "betacoronavirus", "clinical translation", "combat", "coronavirus receptor", "coronavirus vaccine", "cross reactivity", "design", "experimental study", "human coronavirus", "immunogenicity", "interest", "lead candidate", "mutant", "nanoparticle", "nanoparticle delivery", "nanovaccine", "neutralizing antibody", "novel", "novel coronavirus", "nucleic acid delivery", "pandemic disease", "pathogenic virus", "plasmid DNA", "pre-clinical", "programs", "receptor", "receptor binding", "synergism", "universal coronavirus vaccine", "vaccine candidate", "vaccine development", "vaccinology" ], "approved": true } }, { "type": "Grant", "id": "5475", "attributes": { "award_id": "0630969", "title": "Increasing Student Success in Biology & Biotechnology", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "S-STEM-Schlr Sci Tech Eng&Math" ], "program_reference_codes": [], "program_officials": [], "start_date": "2007-01-01", "end_date": "2011-06-30", "award_amount": 495863, "principal_investigator": { "id": 19077, "first_name": "E. Eileen", "last_name": "Gardner", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1411, "ror": "https://ror.org/00k3ayt93", "name": "William Paterson University", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1411, "ror": "https://ror.org/00k3ayt93", "name": "William Paterson University", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "This project provides 12 full scholarships each year over four years to academically talented, low-income Biology and Biotechnology majors, and supports faculty-guided research experiences, tutoring, internships and field trips to industry settings for the scholarship recipients. The project goal is to increase retention and graduation rates, including accelerating degree completion by providing the means for current part-time students to pursue full-time study. The intellectual merit of the project is the preparation of an increased number of well-qualified biologists and biotechnologists, and helping students with the desire to succeed overcome academic disadvantages. The project is led by a Project Director and a Head Mentor with over 50 years of combined experience in teaching, promoting and supervising student research. Its broader impacts are increasing the supply of trained Biology and Biotechnology technicians to meet the growing demand for them in New Jersey (which is home to one of the largest concentrations of pharmaceutical, chemical and other biotechnology-based industries in the world), the region and the nation; and increasing the number of individuals who are members of groups currently underrepresented in these fields earning B.S. degrees. In recent years, 65% of our Biology and Biotechnology majors have been women, 19% have been Hispanic and 17% have been African-American. The success of the project is measured by its impact on closing gaps in the retention and graduation rates for these students compared to the overall rates for our Biology and Biotechnology majors over the past five years. Project results are disseminated through presentations and reports at national and regional meetings, with individual student successes publicized through University publications and press releases to regional media outlets.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "5302", "attributes": { "award_id": "0819132", "title": "PASI: Cutting-edge Topics in Theoretical Statistics and Applications in Genetics and Bioinformatics; Guanajuato, Mexico, June-July 2009", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Unknown", "AMERICAS PROGRAM" ], "program_reference_codes": [], "program_officials": [], "start_date": "2008-09-01", "end_date": "2011-08-31", "award_amount": 99025, "principal_investigator": { "id": 18647, "first_name": "Javier", "last_name": "Rojo", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 357, "ror": "", "name": "William Marsh Rice University", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 357, "ror": "", "name": "William Marsh Rice University", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "This Pan-American Advanced Studies Institutes (PASI) award, jointly supported by the NSF and the Department of Energy (DOE), will take place from June 19 to July 17, 2009 at the Centro de Investigación en Matemáticas (CIMAT) in Guanajuato, Mexico. Organized by Dr. Javier Rojo of Rice University, the PASI will address cutting edge topics in theoretical statistics and applications to genetics and bioinformatics. Top researchers from Costa Rica, Mexico, Uruguay, and the United States will present cutting edge research in the areas of Statistical Finance, Statistical Multivariate Methods, Dimension Reduction, Survival Analysis with Microarray Data, Bioinformatics, and Statistical Genetics. \n\nThe activity will provide 45 young researchers (including advanced PhD students, post-docs, and young faculty) with support for the duration of the Institute. Expected outcomes in this PASI will include: re-energized efforts in Latin America in theoretical statistics and their applications, enhanced collaborations between U.S. and Latin American researchers, and increased student exposure and experience to new fields of knowledge. The PASI results will be disseminated through lecture notes and proceedings to be published through the CIMAT and Rice University technical report series and will be mailed to all the participants. The lecture notes will also be made available on-line.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "10379", "attributes": { "award_id": "75N93022C00044-0-9999-1", "title": "SBIR TOPIC 107 REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON- MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-09-30", "end_date": "2024-09-29", "award_amount": 596519, "principal_investigator": { "id": 24917, "first_name": "TORI", "last_name": "RACE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": null, "abstract": "The hamster is a well-established model for several infectious diseases including influenza and SARS-CoV-2. Lack of hamster reagents has hampered pre-clinical studies of viral pathogenesis, host immunity, and vaccine development. The objectives of this proposal are to produce and test monoclonal antibodies against 10 cytokines and chemokines and 4 T cell surface markers for characterizing cytokine responses and examining T cells activation in the hamster models of respiratory infections. Completion of this project will provide high-affinity monoclonal antibodies that allow investigators to distinguish innate and adaptive inflammatory cytokine and chemokine responses as well as activated T cells, memory T cells, tissue resident memory T cells, and regulatory T cells in the hamster models of infectious diseases.", "keywords": [ "2019-nCoV", "Affinity", "Cell surface", "Cells", "Communicable Diseases", "Generations", "Hamsters", "Immunity", "Immunization", "Immunologics", "Inflammatory", "Influenza", "Memory", "Modeling", "Monoclonal Antibodies", "Mus", "Proteins", "Reagent", "Recombinant Proteins", "Recombinants", "Regulatory T-Lymphocyte", "Research Personnel", "Respiratory Tract Infections", "Serum", "Small Business Innovation Research Grant", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "Testing", "Tissue Sample", "Tissues", "Validation", "Viral Pathogenesis", "chemokine", "cytokine", "infectious disease model", "preclinical study", "response", "vaccine development" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1392, "count": 13920 } } }